XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%

MT Newswires Live

Aug 06

XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.

Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.

Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.

DoveTree will hold exclusive global rights to develop and commercialize any resulting products.

XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557134474"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557134474\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557134474?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557134474","market":"fut","top_or_hot":-1,"title":"XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%","media":"MT Newswires Live","content":"<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-06 12:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557134474","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557134474","pubTimestamp":1754452929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"XtalPi Holdings  finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02228":"晶泰控股","BK1141":"生命科学工具和服务","BK1617":"AI医疗"},"translate_title":"XtalPi与DoveTree敲定药物发现协议；股价飙升8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":0.9},"content_text":"XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}